Journal of Clinical Oncology, Vol 15, 2769-2779, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized study of intensive MOPP-ABVD with or without low-dose total- nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study

MA Weiner, B Leventhal, ML Brecher, RB Marcus, A Cantor, PW Gieser, JL Ternberg, FG Behm, MD Wharam Jr and AR Chauvenet
College of Physicians and Surgeons of Columbia University, New York, USA. mw216@columbia.edu

PURPOSE: To determine whether the addition of low-dose total-nodal irradiation (TNI) in pediatric patients with advanced-stage Hodgkin's disease who have received eight cycles of alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) will improve the event- free survival (EFS) and overall survival (OS) when compared with patients who have received chemotherapy only. PATIENTS AND METHODS: At diagnosis, 183 children and adolescents with stages IIB, IIIA2, IIIB, and IV Hodgkin's disease were randomized to receive eight cycles of alternating MOPP-ABVD with or without low-dose TNI. RESULTS: Of 183 patients, four were rendered ineligible before treatment was initiated. One hundred sixty-one of 179 patients (90%) were in complete remission (CR) at the completion of eight cycles of alternating MOPP-ABVD; 81 were in the chemotherapy-only group and proceeded to observation off therapy, whereas 80 of 161 were to receive combined modality therapy (CMT). Nine of 80 patients randomized at the time of diagnosis to receive CMT did not receive radiation (RT) because of a protocol violation, but were monitored for EFS and OS and included in all analyses. The estimated EFS and OS rates at 5 years for the 179 eligible patients are 79% and 92%, respectively. The actuarial EFS at 5 years was 80% for patients who received CMT and 79% for patients who received MOPP-ABVD only. The OS for the former group is estimated to be 87% and for the latter patients 96%. Age < or = 13 years of age at diagnosis and the attainment of a clinical CR after three cycles of chemotherapy were associated with a statistically significant improved EFS. CONCLUSION: Our results indicate that after the delivery of eight cycles of MOPP-ABVD, the addition of low-dose RT does not improve the estimated EFS or OS in pediatric patients with advanced-stage Hodgkin's disease.

This article has been cited by other articles:

				M. Burke, J. R. Anderson, S. C. Kao, D. Rodeberg, S. J. Qualman, S. L. Wolden, W. H. Meyer, and P. P. Breitfeld Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group J. Clin. Oncol., November 1, 2007; 25(31): 4909 - 4913. [Abstract] [Full Text] [PDF]

				L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al. Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741. [Abstract] [Full Text] [PDF]

				J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]

				C. Ferme, N. Mounier, O. Casasnovas, P. Brice, M. Divine, A. Sonet, F. Bouafia, A. Bastard-Stamatoullas, D. Bordessoule, L. Voillat, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood, June 15, 2006; 107(12): 4636 - 4642. [Abstract] [Full Text] [PDF]

				L. M. Foltz, K. W. Song, and J. M. Connors Hodgkin's Lymphoma in Adolescents J. Clin. Oncol., June 1, 2006; 24(16): 2520 - 2526. [Abstract] [Full Text] [PDF]

				M. J. Krasin, S. N. Rai, L. E. Kun, T. E. Merchant, M. L. Metzger, S. C. Kaste, S. C. Howard, and M. M. Hudson Patterns of Treatment Failure in Pediatric and Young Adult Patients With Hodgkin's Disease: Local Disease Control With Combined-Modality Therapy J. Clin. Oncol., November 20, 2005; 23(33): 8406 - 8413. [Abstract] [Full Text] [PDF]

				M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al. Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550. [Abstract] [Full Text] [PDF]

				S. Laskar, T. Gupta, S. Vimal, M.A. Muckaden, T.K. Saikia, S.K. Pai, K.N. Naresh, and K.A. Dinshaw Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need? J. Clin. Oncol., January 1, 2004; 22(1): 62 - 68. [Abstract] [Full Text] [PDF]

				V. Diehl Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease J. Clin. Oncol., January 1, 2004; 22(1): 15 - 18. [Full Text] [PDF]

				R. S. Smith, Q. Chen, M. M. Hudson, M. P. Link, L. Kun, H. Weinstein, A. Billett, K. J. Marcus, N. J. Tarbell, and S. S. Donaldson Prognostic Factors for Children With Hodgkin's Disease Treated With Combined-Modality Therapy J. Clin. Oncol., May 15, 2003; 21(10): 2026 - 2033. [Abstract] [Full Text] [PDF]

				M. M. Hudson Pediatric Hodgkin's Therapy: Time for a Paradigm Shift J. Clin. Oncol., September 15, 2002; 20(18): 3755 - 3757. [Full Text] [PDF]

				J. B. Nachman, R. Sposto, P. Herzog, G. S. Gilchrist, S. L. Wolden, J. Thomson, M. E. Kadin, P. Pattengale, P. C. Davis, R. J. Hutchinson, et al. Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin's Disease Who Achieve a Complete Response to Chemotherapy J. Clin. Oncol., September 15, 2002; 20(18): 3765 - 3771. [Abstract] [Full Text] [PDF]

				S. S. Donaldson, M. M. Hudson, K. R. Lamborn, M. P. Link, L. Kun, A. L. Billett, K. C. Marcus, C. A. Hurwitz, J. A. Young, N. J. Tarbell, et al. VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin's Disease: Results of a Prospective Clinical Trial J. Clin. Oncol., July 15, 2002; 20(14): 3081 - 3087. [Abstract] [Full Text] [PDF]

				A. M. Friedmann, M. M. Hudson, H. J. Weinstein, S. S. Donaldson, L. Kun, N. J. Tarbell, and M. P. Link Treatment of Unfavorable Childhood Hodgkin's Disease With VEPA and Low-Dose, Involved-Field Radiation J. Clin. Oncol., July 15, 2002; 20(14): 3088 - 3094. [Abstract] [Full Text] [PDF]

				S. J. Horning, J. Williams, N. L. Bartlett, J. M. Bennett, R. T. Hoppe, D. Neuberg, and P. Cassileth Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492 J. Clin. Oncol., March 1, 2000; 18(5): 972 - 972. [Abstract] [Full Text] [PDF]

				G. Schellong, R. Potter, J. Bramswig, W. Wagner, F.-J. Prott, W. Dorffel, D. Korholz, G. Mann, B. Rath, A. Reiter, et al. High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90 J. Clin. Oncol., December 1, 1999; 17(12): 3736 - 3744. [Abstract] [Full Text] [PDF]

				K. S. Baker, B. G. Gordon, T. G. Gross, M. A. Abromowitch, E. R. Lyden, J. C. Lynch, J. M. Vose, J. O. Armitage, P. F. Coccia, and P. J. Bierman Autologous Hematopoietic Stem-Cell Transplantation for Relapsed or Refractory Hodgkin's Disease in Children and Adolescents J. Clin. Oncol., March 1, 1999; 17(3): 825 - 825. [Abstract] [Full Text] [PDF]